Polypharmacy in the Elderly: Geriatric Medication Safety

Renal function declines with aging through decreased glomerular number, proximal tubule length/volume, and GFR. Creatinine clearance formula incorporates age (140 - age × weight kg / 72 × serum creatinine). Decreased muscle mass affects creatinine interpretation—serum creatinine of 1.1-1.2 may be normal in elderly women with reduced muscle mass. Hepatic blood flow and size decrease, reducing phase I drug metabolism capacity. Drugs with high hepatic extraction ratios accumulate. Protein binding changes alter free drug fractions, though standard liver function tests typically appear normal.

After age 40, kidney clearance decreases by approximately 1% per year and liver clearance decreases by approximately 8% per year in healthy abstinent adults. These declines are accelerated by unhealthy behaviors such as drinking alcohol or having fatty liver disease. The reduced organ function directly impacts the body's ability to break down and excrete medications.

Hepatic and renal function decline significantly in elderly patients: (1) Hepatic metabolism decreases, particularly Phase I reactions (CYP3A4, CYP2D6, CYP2C9) more than Phase II; (2) Reduced hepatic blood flow due to arteriosclerosis affects drug delivery; (3) Renal function declines with reduced kidney size, nephron number, and glomerular filtration rate; (4) Reduced tubular secretion affects drug clearance. These changes require careful dose adjustments for renally and hepatically excreted medications.

Reduced glomerular filtration rate (GFR) is a normal physiological change in aging, with GFR declining progressively. For example, a 78-year-old with GFR of 48 may represent normal age-related decline. However, this does not mean the condition is benign; careful medication management is required because reduced renal function affects drug metabolism and clearance.

After age 40, kidney clearance decreases by approximately 1% per year and liver clearance decreases by approximately 0.8% per year in healthy abstinent adults. These declines are accelerated by unhealthy behaviors such as drinking, fatty liver disease, and other conditions. Additionally, many drugs compete for the same liver enzymes (cytochrome P450 family), reducing the body's ability to break down and excrete medications. Cytochrome P450 enzyme activity declines about 16% after age 40 and up to 32% after age 70, further impairing drug metabolism.

La multimorbilidad es una condición caracterizada por la coexistencia de múltiples enfermedades crónicas, dos o más, que generan una presentación clínica compleja que es mucho más que la suma de las enfermedades que coexisten en un individuo. Hay interacción entre esas enfermedades y entre los tratamientos que se brindan a los pacientes. El paciente multimórbido suele tener polifarmacia (muchos medicamentos interactuando al mismo tiempo), tratamientos contrapuestos, y condiciones que determinan fragilidad.

The World Health Organization defines multimorbidity as the co-occurrence of two or more chronic medical conditions in one person, first published in 1976. The term 'comorbidity' has been used interchangeably, causing prevalence estimates to range from 12.9% to 95.1%. Comorbidity is a specialist concept with an 'index condition,' while multimorbidity is a primary care concept where all conditions are equally important. Three research gaps exist: definition (no consensus on number of conditions, types, data sources, or cut points), measurement (four methods exist but purpose is unclear), and outcome measurement (no consensus on important outcomes). Two conceptual frameworks guide research: patient-centered clinical methods (building positive clinician-patient interactions) and minimally disruptive medicine (achieving patient goals with minimal burden).

Multimorbidity refers to the presence of multiple chronic conditions, though definitions vary significantly. Basic definitions simply count conditions (two or more as minimum, three as common threshold). More complex 'count plus' definitions incorporate body systems crossing, severity, symptom burden, and function. Indices like the Charlson, Elixhauser, and Gagne index weight conditions based on mortality risk. Prevalence data shows two-thirds of Medicare beneficiaries have two or more conditions, nearly 90% of veterans over 65 have three or more, and just under half of primary care patients over 18 have two or more conditions. Multimorbidity affects not just the elderly but also younger patients, particularly in VA settings where mental illness and chronic pain are common.

Multimorbidity refers to patients who have multiple disease conditions simultaneously in one person. When a person has severe obesity combined with other health conditions, they are classified as multimorbide patients, meaning they face compounded health challenges from having several diseases at once.

Multimorbidity refers to the presence of multiple chronic conditions in a single patient, typically more than one. The key challenge is that physicians can take two separate issues and make them seem like four, creating unnecessary complexity. The goal of managing multimorbidity is to streamline care and make things appear simpler rather than more complicated.

Adverse drug reactions are harmful effects of medications, classified into predictable (Type A) and unpredictable (Type B) categories, with predictable reactions including side effects, secondary effects, overdose, supersensitivity, tolerance, addiction, etiogenic effects, cytotoxic effects, and drug interactions; drug interactions occur when two or more drugs affect each other's actions through pharmacokinetic (absorption, distribution, metabolism, excretion) or pharmacodynamic (receptor-level) mechanisms, producing outcomes ranging from additive to synergistic, potentiating, or antagonistic effects.

An adverse drug reaction (ADR) is an unintended and harmful effect of a drug that occurs when taken for its intended purpose. The term 'adverse' means opposite to expectations. ADRs can result from various causes including expired medicines, overdose (taking more than prescribed), drug interactions, allergies, and stopping medication abruptly. ADRs are classified into predictable/dose-dependent (Type A) and unpredictable/idiosyncratic (Type B) categories. Type A reactions are common, dose-related, and often preventable, while Type B reactions are rare, unpredictable, and often more severe. Understanding these fundamentals is essential for safe medication use and patient safety.

Adverse drug reactions (ADRs) are noxious and unintended responses to medications at normal therapeutic doses. The WHO definition excludes pharmacological inefficacy, while French and FDA definitions are broader, including overdose, withdrawal, and therapeutic errors. ADRs occur through four mechanisms: toxic (dose-dependent), idiosyncratic (genetic particularity), immune (allergic reactions), and pharmacological (off-target effects). Events independent of drug effect result from patient-physician interactions and are psychogenic. ADRs are classified as dose-dependent (Type A) or dose-independent (Type B). Type A reactions are predictable, dose-dependent, and preventable through proper dosing, with examples including NSAID toxicity, antidepressant anticholinergic effects, and anticoagulant bleeding. Causes include pharmacokinetic modifications, drug interactions (10-20% of events), and incorrect dosing. Type B reactions are unpredictable, occurring in limited subjects with severe consequences, including hypersensitivity and allergic reactions where anaphylaxis is most serious. Four types of hypersensitivity exist: Type I (immediate/anaphylactic), Type II (cytotoxic), Type III (immune complex), and Type IV (delayed). Prevention relies on thorough medication history questioning.

An adverse drug reaction (ADR) is defined as any untoward medical occurrence that takes place during the treatment period with the use of a pharmaceutical product. ADRs are classified into types: Type A (Augmented) are predictable, dose-dependent reactions related to the drug's pharmacological action; Type B (Bizarre) are unpredictable, non-dose-dependent reactions often idiosyncratic; Type C (Chronic) occur with long-term drug use; Type D (Delayed) appear after treatment discontinuation; Type E (End of Treatment) are withdrawal symptoms; Type F (Failure of Treatment) occur when the drug fails to achieve its therapeutic effect. ADRs can occur through mechanisms including exaggerated effects, altered effects, allergic reactions, genetic factors, and binding to unintended receptors.

Adverse drug reactions (ADRs) are unintended, harmful responses to medications at normal therapeutic doses, classified into five types: Type A (dose-dependent, predictable effects like increased drug action), Type B (idiosyncratic, unpredictable immune-mediated reactions like anaphylaxis), Type C (dose- and time-dependent chronic effects like adrenal suppression), Type D (time-dependent delayed effects like carcinogenesis), Type E (withdrawal effects upon discontinuation), and Type F (treatment failure due to drug interactions). Drug interactions occur when co-administered substances alter drug effects through pharmacokinetic mechanisms (absorption, distribution, metabolism, excretion) or pharmacodynamic mechanisms (additive, synergistic, or antagonistic effects).